ENB003
ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.
Overview
ENB003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ENB Therapeutics, Inc, in melanoma. Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording.
1.ENB003 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"ENB003" OR ABSTRACT:"ENB003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ENB003, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPRTX007
Shares Melanoma and the tags pipeline, registry-only.
- TreatmentAU-007
Shares Melanoma and the tags pipeline, registry-only.
- TreatmentOR502
Shares Melanoma and the tags pipeline, registry-only.
- TreatmentDOC1021
Shares Melanoma and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares the tags pipeline, registry-only.
- TreatmentAlisertib
Shares the tags pipeline, registry-only.
- TreatmentAMO959
Shares the tags pipeline, registry-only.
- TreatmentAMT-116
Shares the tags pipeline, registry-only.